I don't want to spend a lot of time writing a reply to your very good question. I will try to be brief....(Brief?? ...Good luck Pro-Advisor!)
Suffice it to say that things are significantly different, say from what happened a year ago, however, things are actually quite similar to the conditions that existed at the time the video was recorded. I'm very aware of that video and it does seem to cast a pall on the current situation, however, BioRestorative is in a significantly different position today.
What changed from the time of the video until the bankruptcy occurrence last year was that the previous CEO started to behave in a fashion that progressively bled the company dry in a myriad of different ways. Besides high salaries, primarily his own, and offers for note payments that were very lucrative for the investor, I being one of them, the most important work of all, to get funding, was not being done. The fact of the matter is that the capital on hand during that time was egregiously misused and wasted.
The CEO was not connected to the financing necessary to move the company forward, did not work hard, taking too much time away from the office plus he never prepared a trials protocol which was necessary to lure funding and show intent. An FDA testing protocol can take a year or longer and it wasn't being done, nothing in preparation, nothing was happening and investors wanted their notes paid up for which Peter could not or would no longer pay Paul if you get the drift. The CEO, under the auspices of Board of Directors approval, was paying huge dividends to people who loaned the company money, with up to 20% payouts for a two month note along with shares of stock. This was short-term double-digit interest payoffs. How long can a small under-funded company sustain that? Apparently we know the answer to that question, don't we? It cannot!
Lance is a completely different leader. He's quite aware of went down before from the inside because, after-all, he was a board member. Lance reduced salaries to reasonable, fair levels, He brought in Dr. Kukekov, who was a Senior Managing Director at Paulson Investment Company who has excellent contacts into the investment community and probably has prospects for funding for the FDA trials already. Those things should have been done but were never accomplished until now. Plus there is more which I don't have time to address at the moment, however, I think these are huge changes! Don't you?
Therefore, the similarities are there but there are big differences which will help the company move forward. The keyword is patience.
I hope that casts a little bit of light on the situation.
As far as dilution goes...... to be continued...
